| Methods |
Randomised controlled trial (prior to 1997) |
| Participants |
Individuals with Stage IIIA NSCLC with biopsy proven mediastinal node involvement and fit for surgery with predicted post‐operative FEV1 of > 0.8L. ECOG performance status of less than or equal to 2. |
| Interventions |
Intervention group: induction chemotherapy followed by surgical resection;
Control group: radiotherapy (60Gy) |
| Outcomes |
Response rates, toxicity and treatment related morbidity and mortality. Survival at 2 years. |
| Notes |
Trial closed prematurely
C‐factor staging: C2/3 (biopsy proven mediastinal node involvement)
Staging classification criteria not described |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Information not reported. After contacting the authors, generation of sequence was reclassified as adequate (computer generated) |
| Allocation concealment? |
Low risk |
Information not reported. After contacting the authors, allocation concealment was reclassified as adequate |
| Blinding?
All outcomes |
Unclear risk |
Information not reported |
| Incomplete outcome data addressed?
All outcomes |
Low risk |
Information not reported. After contacting the authors it was confirmed that there were no losses to follow up |
